2024 CUDA | Dr. Qiang Wei: Precision Medicine Opens a New Chapter in Prostate Cancer Patient Benefits

2024 CUDA | Dr. Qiang Wei: Precision Medicine Opens a New Chapter in Prostate Cancer Patient Benefits

In the spirit of "Healthy China, Urology First," the 2024 Annual Meeting of the Chinese Urological Association (CUDA) was grandly held in Xi'an, Shaanxi Province, from August 8th to 11th, 2024. The event showcased the latest achievements in urological medicine from a global and multidimensional perspective. In recent years, with the deepening of molecular exploration, prostate cancer treatment has entered the era of precision medicine. Urology Frontier invited Dr. Qiang Wei from West China Hospital, Sichuan University, to discuss the significance, recent breakthroughs, and future applications of precision medicine in prostate cancer.
2024 CUDA | Dr. Shun Zhang: Standardizing the Management of Prostate Cancer Bone Metastases to Maximize Patient Benefits

2024 CUDA | Dr. Shun Zhang: Standardizing the Management of Prostate Cancer Bone Metastases to Maximize Patient Benefits

Prostate cancer is one of the most common malignant tumors in the male urinary system, with over 110,000 new cases diagnosed annually in China. The bones are the primary site of metastasis for prostate cancer, leading to bone-related events (BREs) such as pathological fractures, spinal cord compression, and bone pain, which significantly impact patients' quality of life and long-term prognosis. Studies have shown that 60%-75% of prostate cancer patients with bone metastases experience severe bone pain at diagnosis, causing substantial disruption to their daily lives. Bone-related events, represented by bone pain, accompany the entire course of disease progression in prostate cancer bone metastasis patients, imposing a heavy economic burden on patients, families, and society. Urology Frontier has invited Dr. Shun Zhang from Medical School of Nanjing University Affiliated Nanjing Drum Tower Hospital to share insights on this topic.
AIDS Five Minutes | Dr. Wei Cao: Treatment and Management Practices in the Post-HAART Era of HIV

AIDS Five Minutes | Dr. Wei Cao: Treatment and Management Practices in the Post-HAART Era of HIV

"The continuous advancements and remarkable success of Highly Active Antiretroviral Therapy (HAART) have made long-term survival for HIV patients a reality. However, the persistent presence of the HIV virus, chronic inflammation associated with the virus, and the lifelong impact of medication have led to chronic complications, such as metabolic diseases, becoming significant factors affecting the clinical outcomes of patients undergoing long-term treatment. These issues have become crucial in the treatment and management of patients. One of the key focuses of the 25th International AIDS Conference (AIDS2024) was the ongoing attention to non-AIDS-related complications, which brought new insights into their treatment and management."
AIDS China Voice | Dr. Biao Zhu: Changing Disease Spectrum of Hospitalized HIV-Infected Patients in Eastern China

AIDS China Voice | Dr. Biao Zhu: Changing Disease Spectrum of Hospitalized HIV-Infected Patients in Eastern China

From July 22-26, 2024, the 25th International AIDS Conference（AIDS 2024） was held in Munich, Germany, bringing together 15,000 professionals and advocates from around the world to discuss the latest advancements and future challenges in HIV prevention and treatment. At the conference, Dr. Biao Zhu from the First Affiliated Hospital,Zhejiang University School of Medicine presented a retrospective study conducted by his team. The report analyzed the changing disease spectrum of hospitalized HIV-infected patients in comprehensive hospitals in Eastern China over the past 12 years, revealing not only the survival status of HIV-infected patients in the Yangtze River Delta region but also significant changes in their disease spectrum as they achieve long-term survival.
Dr. Qian Jiang Elaborates on Standard Treatment Models and Unmet Needs in Newly Diagnosed Chronic Myeloid Leukemia | The 8th CSCO Hematology Academic

Dr. Qian Jiang Elaborates on Standard Treatment Models and Unmet Needs in Newly Diagnosed Chronic Myeloid Leukemia | The 8th CSCO Hematology Academic

To further enhance the diagnostic and treatment techniques for leukemia and lymphoma in China, the 8th Hematology Oncology Academic Conference was held from July 26 to 28 in Harbin. This event was jointly organized by the Chinese Society of Clinical Oncology (CSCO), the CSCO Leukemia Expert Committee, and the Lymphoma Expert Committee, and co-hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital. The conference aimed to provide a significant platform for in-depth learning and extensive exchange among experts and scholars in the field of hematologic oncology. On this occasion, Hematology Frontier had the privilege of inviting Dr. Qian Jiang from Peking University People's Hospital to share her insights on the treatment models and unmet needs for newly diagnosed chronic myeloid leukemia (CML) patients.
Diabetes Increases the Risk of Death or Liver Transplantation in Patients with Alcoholic Cirrhosis

Diabetes Increases the Risk of Death or Liver Transplantation in Patients with Alcoholic Cirrhosis

Over time, alcohol consumption has become a significant public health concern. Alcohol is associated with more than 200 diseases, including diabetes and cirrhosis, contributing to 5.3% of global mortality. Despite increased awareness of alcohol's harmful effects, overall consumption levels have not decreased. Previous studies have investigated the impact of diabetes on patients with alcoholic cirrhosis, but the relationship between diabetes and clinical outcomes in these patients has remained unclear. Recently, a study published in Hepatology International has shed light on the relationship between diabetes and clinical outcomes in patients with alcohol-related cirrhosis.
CDM Monthly Review · Issue 83

CDM Monthly Review · Issue 83

Greetings to all experts and colleagues. In this issue of CDM Monthly Review (Issue 83), we will share five recent papers in the field of diagnosis and treatment of portal hypertension in liver cirrhosis (three on diagnostic monitoring and two on multidisciplinary treatment). The guest experts for this issue's review are Dr. Qianwen Zhao from the Department of Infectious Diseases at Nanjing Drum Tower Hospital, Dr. Yanna Liu from the Liver Disease and Gastroenterology Center at Beijing You'an Hospital , Capital Medical University, Dr. Kefeng Jia from Tianjin Third Central Hospital, and Dr. Wenhui Zhang from the Department of Gastroenterology at Beijing Daxing District People's Hospital.
JOH丨Impact of Pre-Transplant Immunotherapy on Post-Transplant Outcomes in Liver Cancer

JOH丨Impact of Pre-Transplant Immunotherapy on Post-Transplant Outcomes in Liver Cancer

The Journal of Hepatology (JOH) recently published an online systematic review and individual patient data meta-analysis conducted by Cedars-Sinai Medical Center in Los Angeles. The study investigates the impact of using immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) before liver transplantation on various key clinical outcomes post-transplantation. The findings reveal that while ICIs treatment may increase the risk of post-transplant rejection, the overall risk remains manageable, with patient age and ICI clearance time being closely related to rejection risk. This study provides valuable clinical data to support the use of ICIs before liver transplantation, offering new insights and directions for research and clinical practice in this area.
Artificial Liver Support System Improves Gut Microbiota and Serum Bile Acids in Patients with Acute-on-Chronic Liver Failure

Artificial Liver Support System Improves Gut Microbiota and Serum Bile Acids in Patients with Acute-on-Chronic Liver Failure

Most patients with acute-on-chronic liver failure (ACLF) exhibit varying degrees of cholestasis. Previous studies have shown that compared to standard medical treatment alone, the artificial liver support system (ALSS) can improve prognosis and extend survival time in ACLF patients. Additionally, research has confirmed gut microbiota dysbiosis in ACLF patients. However, the specific impact of ALSS on the gut microbiota composition in these patients remains unclear. Considering the complex interactions between gut microbiota, bile acids (BAs), and the liver, researchers conducted a study to elucidate the unique effects of ALSS on gut microbiota and serum BAs in ACLF patients. Furthermore, the study visualized the relationships between gut microbiota, serum BAs, and clinical outcomes in ACLF patients using correlation heatmaps, providing insights into potential therapeutic targets for ACLF. The study was recently published in Hepatology International.
Interview with Dr. Bijie Hu, Chairman of the 2024 SIFIC Conference

Interview with Dr. Bijie Hu, Chairman of the 2024 SIFIC Conference

Since its inception in 2005, the Shanghai International Forum for Infection Control (SIFIC) has grown over the past two decades. Known for its professionalism and forward-thinking approach, SIFIC has become a significant academic platform in China for the fields of hospital infection, major infectious diseases, and the prevention and control of multidrug-resistant organisms. Each year's academic conference not only boasts a large scale but also serves as a grand academic gathering for infection control experts and scholars from both domestic and international arenas. In the recently concluded SIFIC 2024 conference, one of the founders and current Chairman of SIFIC, Dr. Bijie Hu from Zhongshan Hospital, Fudan University, shared with Infectious Disease Frontier the development and achievements of SIFIC, as well as his profound insights into the future of infection control in China. Through his perspective, we gain a glimpse into the evolution of the field, the challenges it currently faces, and the direction it is likely to take in the future.